Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Deciphering novel UPS regulation of Sgf73/ataxin-7 in controlling SAGA and associated functions in gene expression

Award Number: R15CA290595
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2025
PERIOD OF PERFORMANCE END DATE: 08/31/2028

Group Awards By:

View Award Description

Deciphering novel UPS regulation of Sgf73/ataxin-7 in controlling SAGA and associated functions in gene expression - ABSTRACT: Sgf73/ataxin-7 is a key component of an evolutionarily conserved transcriptional co-activator SAGA (Spt-Ada-Gcn5-Acetyltransferase) with two distinct enzymatic activities for chromatin modifications, and is up- and downregulated in cancer and other diseases such as eye and neurological disorders. Therefore, it is crucial to understand the regulatory networks lying upstream of Sgf73 towards understanding the pathogenesis of these diseases with targeted therapeutic interventions. However, it remains largely unknown how Sgf73 is regulated. In view of this, we carried out a set of experiments which demonstrated ubiquitylation and proteasomal degradation of Sgf73, thus revealing a novel UPS (Ubiquitin-proteasome system) regulation of Sgf73. However, the E3 ubiquitin ligase involved in such regulation of Sgf73 is yet unknown. Further, the physiological relevance of such regulation of Sgf73 on SAGA’s integrity and functions in controlling gene expression remains largely elusive. Moreover, other factors such as ubiquitin protease and conjugase involved in Sgf73 ubiquitylation and proteasomal degradation are not yet known. Answers to these important questions would fundamentally establish novel UPS regulation of Sgf73 in orchestrating gene expression, thus greatly advancing the field of gene regulation. In addition, these results would have significant impact on understanding the pathogenesis of cancer and other diseases such as eye and neurological disorders and future therapeutic development, since Sgf73 is associated with these diseases. Therefore, we propose to address above questions in this application. Specifically, we aim to (i) identify E3 ubiquitin ligase involved in Sgf73 ubiquitylation and proteasomal degradation, (ii) determine ubiquitylation site on Sgf73, (iii) determine the physiological relevance/roles of Sgf73 ubiquitylation and proteasomal degradation in regulation of SAGA’s integrity and functions in gene expression in controlling cellular health, and (iv) identify ubiquitin conjugase, ubiquitin protease and other factors involved in regulation of Sgf73 ubiquitylation and proteasomal degradation with associated functions. Collective results would identify new factors involved in regulation of Sgf73 with roles in controlling SAGA and gene expression in maintaining cellular functions, thus fundamentally advancing our understanding of gene regulation by UPS with implications in human health.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $445,500 )
2025	2025	BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY	900 S NORMAL AVE	CARBONDALE	IL	62901	JACKSON	USA	Cancer Biology Research	000	1	8/8/2025	NEW	$445,500
														Subtotal = $445,500

Grand Total All Awards = $445,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Deciphering novel UPS regulation of Sgf73/ataxin-7 in controlling SAGA and associated functions in gene expression

Award Number: R15CA290595

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2025

PERIOD OF PERFORMANCE END DATE: 08/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer